DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, C. G. | ko |
dc.contributor.author | Kim, K. H. | ko |
dc.contributor.author | Pyo, K-H | ko |
dc.contributor.author | Xin, C-F | ko |
dc.contributor.author | Hong, M. H. | ko |
dc.contributor.author | Ahn, B-C | ko |
dc.contributor.author | Kim, Y. | ko |
dc.contributor.author | Choi, S. J. | ko |
dc.contributor.author | Yoon, H., I | ko |
dc.contributor.author | Lee, J. G. | ko |
dc.contributor.author | Lee, C. Y. | ko |
dc.contributor.author | Park, S. Y. | ko |
dc.contributor.author | Park, S-H | ko |
dc.contributor.author | Cho, B. C. | ko |
dc.contributor.author | Shim, H. S. | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.contributor.author | Kim, H. R. | ko |
dc.date.accessioned | 2019-09-24T12:20:57Z | - |
dc.date.available | 2019-09-24T12:20:57Z | - |
dc.date.created | 2019-09-24 | - |
dc.date.created | 2019-09-24 | - |
dc.date.created | 2019-09-24 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.citation | ANNALS OF ONCOLOGY, v.30, no.7, pp.1104 - 1113 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | http://hdl.handle.net/10203/267677 | - |
dc.description.abstract | Background Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been effective in various malignancies and is considered as a standard treatment modality for patients with non-small-cell lung cancer (NSCLC). However, emerging evidence show that PD-1/PD-L1 blockade can lead to hyperprogressive disease (HPD), a flair-up of tumor growth linked to dismal prognosis. This study aimed to evaluate the incidence of HPD and identify the determinants associated with HPD in patients with NSCLC treated with PD-1/PD-L1 blockade. Patients and methods We enrolled patients with recurrent and/or metastatic NSCLC treated with PD-1/PD-L1 inhibitors between April 2014 and November 2018. Clinicopathologic variables, dynamics of tumor growth, and treatment outcomes were analyzed in patients with NSCLC who received PD-1/PD-L1 blockade. HPD was defined according to tumor growth kinetics (TGK), tumor growth rate (TGR), and time to treatment failure (TTF). Immunophenotyping of peripheral blood CD8(+) T lymphocytes was conducted to explore the potential predictive biomarkers of HPD. Results A total of 263 patients were analyzed. HPD was observed in 55 (20.9%), 54 (20.5%), and 98 (37.3%) patients according to the TGK, TGR, and TTF. HPD meeting both TGK and TGR criteria was associated with worse progression-free survival [hazard ratio (HR) 4.619; 95% confidence interval (CI) 2.868-7.440] and overall survival (HR, 5.079; 95% CI, 3.136-8.226) than progressive disease without HPD. There were no clinicopathologic variables specific for HPD. In the exploratory biomarker analysis with peripheral blood CD8(+) T lymphocytes, a lower frequency of effector/memory subsets (CCR7(-)CD45RA(-) T cells among the total CD8(+) T cells) and a higher frequency of severely exhausted populations (TIGIT(+) T cells among PD-1(+)CD8(+) T cells) were associated with HPD and inferior survival rate. Conclusion HPD is common in NSCLC patients treated with PD-1/PD-L1 inhibitors. Biomarkers derived from rationally designed analysis may successfully predict HPD and worse outcomes, meriting further investigation of HPD. | - |
dc.language | English | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.title | Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer | - |
dc.type | Article | - |
dc.identifier.wosid | 000484369900016 | - |
dc.identifier.scopusid | 2-s2.0-85066114349 | - |
dc.type.rims | ART | - |
dc.citation.volume | 30 | - |
dc.citation.issue | 7 | - |
dc.citation.beginningpage | 1104 | - |
dc.citation.endingpage | 1113 | - |
dc.citation.publicationname | ANNALS OF ONCOLOGY | - |
dc.identifier.doi | 10.1093/annonc/mdz123 | - |
dc.contributor.localauthor | Park, S-H | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Pyo, K-H | - |
dc.contributor.nonIdAuthor | Xin, C-F | - |
dc.contributor.nonIdAuthor | Hong, M. H. | - |
dc.contributor.nonIdAuthor | Ahn, B-C | - |
dc.contributor.nonIdAuthor | Kim, Y. | - |
dc.contributor.nonIdAuthor | Choi, S. J. | - |
dc.contributor.nonIdAuthor | Yoon, H., I | - |
dc.contributor.nonIdAuthor | Lee, J. G. | - |
dc.contributor.nonIdAuthor | Lee, C. Y. | - |
dc.contributor.nonIdAuthor | Park, S. Y. | - |
dc.contributor.nonIdAuthor | Cho, B. C. | - |
dc.contributor.nonIdAuthor | Shim, H. S. | - |
dc.contributor.nonIdAuthor | Kim, H. R. | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | NSCLC | - |
dc.subject.keywordAuthor | tumor growth dynamics | - |
dc.subject.keywordAuthor | PD-1/PD-L1 blockade | - |
dc.subject.keywordAuthor | hyperprogressive disease | - |
dc.subject.keywordAuthor | biomarkers | - |
dc.subject.keywordPlus | IMMUNE CHECKPOINT BLOCKADE | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | PEMBROLIZUMAB | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | HEAD | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.